Eviagenics is a French biotech company that harnesses the best performing technology platform for the rapid and efficient generation of cellular factories devoted to the production of various high-value chemical molecules of commercial use. By developing its proprietary in vivo recombination technology, the company has achieved a double breakthrough in the field of synthetic biology, enabling:
- One-step optimisation of complete metabolic pathways. In vivo recombination is the only technology that allows to rapidly evolve long DNA sequences ( >20.000 base pairs) compared to other rival technologies, as well as a significant reduction of development time and costs;
- Significant improvements within these cellular factories, such as production yield, as well as generation of new products.
Eviagenics is now focusing on industrial and commercial applications of its technological platform, through (i) collaboration with key players in the field of the chemical and pharmaceutical industry as well as (ii) the development of high-value in-house products.